HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.